Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome
Ning Weng1, Ivan Jeanne Weiler, Allison Sumis
1Beckman Institute, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Abstract:
Lack of production of the Fragile X Mental Retardation Protein (FMRP) leads to changes in dendritic morphology and resultant cognitive and behavioral manifestations characteristic of individuals with Fragile X syndrome (FXS). FMRP is an RNA-binding protein that is believed to regulate the translation of a large number (probably over 100) of other proteins, leading to a complex and variable set of symptoms in FXS. In a mouse model of FXS, we previously observed delayed initiation of synaptically localized protein synthesis in response to neurotransmitter stimulation, as compared to wild-type mice. We now likewise have observed delayed early-phase phosphorylation of extracellular-signal regulated kinase (ERK), a nodal point for cell signaling cascades, in both neurons and thymocytes of fmr-1 KO mice. We further report that early-phase kinetics of ERK activation in lymphocytes from human peripheral blood is delayed in a cohort of individuals with FXS, relative to normlal controls, suggesting a potential biomarker to measure metabolic status of disease for individuals with FXS.
Insights
Fragile X Mental Retardation Protein (FMRP) deficiency causes delayed ERK activation in neurons and lymphocytes. This finding in Fragile X syndrome (FXS) suggests a potential biomarker for disease metabolic status.
Area of Science:
- Neuroscience
- Molecular Biology
- Immunology
Background:
- Fragile X syndrome (FXS) is caused by the lack of Fragile X Mental Retardation Protein (FMRP).
- FMRP deficiency leads to altered dendritic morphology and complex cognitive/behavioral symptoms.
- Previous studies in FXS mouse models showed delayed protein synthesis.
Purpose of the Study:
- To investigate the kinetics of extracellular-signal regulated kinase (ERK) activation in FXS.
- To determine if ERK activation delays are present in both neuronal and non-neuronal cells in FXS models.
- To explore the potential of ERK activation as a biomarker for FXS.
Main Methods:
- Utilized an fmr-1 knockout (KO) mouse model of FXS.
- Measured early-phase phosphorylation of ERK in neurons and thymocytes of fmr-1 KO mice.
- Assessed ERK activation kinetics in peripheral blood lymphocytes from human FXS patients and controls.
Main Results:
- Observed delayed early-phase ERK phosphorylation in neurons and thymocytes of fmr-1 KO mice.
- Demonstrated delayed early-phase ERK activation kinetics in lymphocytes of individuals with FXS compared to controls.
- Identified a potential correlation between FMRP levels and ERK activation timing.
Conclusions:
- Delayed ERK activation is a conserved feature in both mouse models and human patients with FXS.
- Early-phase ERK activation kinetics in lymphocytes may serve as a biomarker for FXS metabolic status.
- Further research is warranted to validate ERK activation as a reliable biomarker for FXS management.
More Related Videos
09:58An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
Published on: May 2, 2025
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Related Concept Videos
01:31Regulation of the Unfolded Protein Response
01:37The Unfolded Protein Response